BiotechTube
ADORA Life Science

ADORA Life Science

San Diego, United States· Est.
adoralifescience.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

ADORA Life Science is a private, preclinical-stage biotech founded in 2018, pioneering a novel polysulfated glycosaminoglycan (PSGAG) platform for osteoarthritis. The company is targeting an $8B+ global osteoarthritis market with a potential first-in-class topical DMOAD, backed by strong IP protection extending to 2043. Led by an experienced team with prior successful exits, ADORA is advancing its lead program toward human clinical development while leveraging existing veterinary use data.

OsteoarthritisInflammatory Pain

Technology Platform

Patented polysulfated glycosaminoglycan (PSGAG) technology platform, repurposing a veterinary disease-modifying antiarthritic for human use via novel topical dosage forms.

Opportunities

Addressing a massive ($8B+) global osteoarthritis market with no approved disease-modifying drugs.
A topical formulation offers a differentiated safety and convenience profile.
Strong IP protection until 2043 provides long-term exclusivity potential.

Risk Factors

High clinical development risk in translating veterinary data to human disease modification.
Significant future capital requirements for costly OA trials.
Intense competition in the osteoarthritis space from numerous biopharma companies.

Competitive Landscape

The osteoarthritis therapeutic landscape is crowded with companies pursuing pain relief and disease modification, but no DMOAD is yet approved. ADORA competes with firms developing injectable biologics, gene therapies, and small molecules. Its differentiation lies in a topical DMOAD approach with a compound having a long prior use history.

More companies in Drug Delivery & Formulation →More companies in United States →